Clinical Trial

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.
Protocol Amendment History 1 change
notable Trial sites expanded: 4 -> 9 locations 2026-06-10
Trial Details
NCT Number NCT07165132
Lead Sponsor RayzeBio, Inc.
Conditions GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET, Solid Tumor +1 more
Enrollment 104 participants
Start Date 2025-12-03
Primary Completion 2027-02 (estimated)
Study Completion 2033-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-09